These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29219879)

  • 1. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity.
    Voelcker G
    Anticancer Drugs; 2018 Jan; 29(1):75-79. PubMed ID: 29219879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine.
    Voelcker G; Pfeiffer B; Schnee A; Hohorst H
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):74-8. PubMed ID: 10664245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostimulating and cancer-reductive experimental therapy with the oxazaphosphorine cytostatic SUM-IAP.
    Voelcker G
    Anticancer Drugs; 2018 Jun; 29(5):411-415. PubMed ID: 29465464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of antitumor activity of the oxazaphosphorine cytostatic SUM-IAP by N-methylformamide.
    Voelcker G
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1183-9. PubMed ID: 26941190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enantioselective cytotoxic activity of bromine-substituted analogues of ifosfamide. A microsomal implication.
    Hładoń B; Sloderbach A; Laskowska H
    Pol J Pharmacol; 1997; 49(2-3):127-36. PubMed ID: 9437759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxazaphosphorine cytostatics: from serendipity to rational drug design.
    Voelcker G
    Anticancer Drugs; 2019 Jun; 30(5):435-440. PubMed ID: 30855309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glufosfamide as a new oxazaphosphorine anticancer agent.
    Mazur L; Opydo-Chanek M; Stojak M
    Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
    Opydo-Chanek M; Mazur L; Stojak M
    Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldophosphamide-thiazolidine (NSC-613060) an oxazaphosphorine cytostatic that crosses the blood brain barrier.
    Voelcker G
    Anticancer Drugs; 2021 Jan; 32(1):61-65. PubMed ID: 32701559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure/activity studies with thiazolidinyl- and perhydrothiazinylphosphamide ester.
    Voelcker G; Hohorst HJ
    J Cancer Res Clin Oncol; 1998; 124(6):297-300. PubMed ID: 9692835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and transport of oxazaphosphorines and the clinical implications.
    Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
    Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causes and possibilities to circumvent cyclophosphamide toxicity.
    Voelcker G
    Anticancer Drugs; 2020 Jul; 31(6):617-622. PubMed ID: 32044797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
    Jones B; Komarnitsky P; Miller GT; Amedio J; Wallner BP
    Anticancer Drugs; 2012 Feb; 23(2):173-84. PubMed ID: 22027537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of 1-aldofosfamide-perhydrothiazines.
    Zimmermann J; Bauer HH; Hohorst HJ; Voelcker G
    Arzneimittelforschung; 2000 Sep; 50(9):843-7. PubMed ID: 11050703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.
    Skarbek C; Lesueur LL; Chapuis H; Deroussent A; Pioche Durieu C; Daville A; Caron J; Rivard M; Martens T; Bertrand JR; Le Cam E; Vassal G; Couvreur P; Desmaele D; Paci A
    J Med Chem; 2015 Jan; 58(2):705-17. PubMed ID: 25494842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport.
    Pohl J; Bertram B; Hilgard P; Nowrousian MR; Stüben J; Wiessler M
    Cancer Chemother Pharmacol; 1995; 35(5):364-70. PubMed ID: 7850916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.
    Storme T; Deroussent A; Mercier L; Prost E; Re M; Munier F; Martens T; Bourget P; Vassal G; Royer J; Paci A
    J Pharmacol Exp Ther; 2009 Feb; 328(2):598-609. PubMed ID: 19017849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of ifosfamide.
    Furlanut M; Franceschi L
    Oncology; 2003; 65 Suppl 2():2-6. PubMed ID: 14586139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
    Takamizawa A; Matsumoto S; Iwata T; Makino I; Yamaguchi K; Uchida N; Kasai H; Shiratori O; Takase S
    J Med Chem; 1978 Feb; 21(2):208-14. PubMed ID: 621716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.